$37.87
4.79% yesterday
Nasdaq, Aug 12, 10:00 pm CET

Collegium Pharmaceutical, Inc. Stock price

$37.87
+5.04 15.35% 1M
+7.34 24.04% 6M
+9.22 32.18% YTD
+2.25 6.32% 1Y
+19.07 101.44% 3Y
+19.62 107.51% 5Y
+20.36 116.28% 10Y
+25.58 208.14% 20Y
Nasdaq, Closing price Tue, Aug 12 2025
+1.73 4.79%

Key metrics

Basic
Market capitalization
$1.1b
Enterprise Value
$1.8b
Net debt
$639.9m
Cash
$197.8m
Shares outstanding
32.1m
Valuation (TTM | estimate)
P/E
27.2 | 5.1
P/S
1.7 | 1.5
EV/Sales
2.7 | 2.3
EV/FCF
9.0
P/B
4.9
Financial Health
Equity Ratio
13.8%
Return on Equity
30.2%
ROCE
11.4%
ROIC
6.4%
Debt/Equity
3.6
Financials (TTM | estimate)
Revenue
$664.3m | $760.7m
EBITDA
$321.1m | $446.4m
EBIT
$130.8m | $291.4m
Net Income
$43.9m | $225.8m
Free Cash Flow
$196.6m
Growth (TTM | estimate)
Revenue
17.2% | 20.5%
EBITDA
-5.1% | 31.7%
EBIT
-31.8% | 71.5%
Net Income
-52.9% | 226.4%
Free Cash Flow
-36.2%
Margin (TTM | estimate)
Gross
57.7%
EBITDA
48.3% | 58.7%
EBIT
19.7%
Net
6.6% | 29.7%
Free Cash Flow
29.6%
More
EPS
$1.3
FCF per Share
$6.1
Short interest
15.6%
Employees
357
Rev per Employee
$1.8m
Show more

Is Collegium Pharmaceutical, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Collegium Pharmaceutical, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Collegium Pharmaceutical, Inc. forecast:

9x Buy
82%
2x Hold
18%

Analyst Opinions

11 Analysts have issued a Collegium Pharmaceutical, Inc. forecast:

Buy
82%
Hold
18%

Financial data from Collegium Pharmaceutical, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
664 664
17% 17%
100%
- Direct Costs 281 281
24% 24%
42%
383 383
13% 13%
58%
- Selling and Administrative Expenses 245 245
65% 65%
37%
- Research and Development Expense - -
-
-
321 321
5% 5%
48%
- Depreciation and Amortization 190 190
30% 30%
29%
EBIT (Operating Income) EBIT 131 131
32% 32%
20%
Net Profit 44 44
53% 53%
7%

In millions USD.

Don't miss a Thing! We will send you all news about Collegium Pharmaceutical, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Collegium Pharmaceutical, Inc. Stock News

Neutral
Seeking Alpha
5 days ago
Collegium Pharmaceutical, Inc. (NASDAQ:COLL ) Q2 2025 Earnings Conference Call August 7, 2025 8:00 AM ET Company Participants Colleen Tupper - Executive VP & CFO Ian Karp - Corporate Participant Scott Dreyer - Executive VP & Chief Commercial Officer Vikram Karnani - CEO, President, Executive VP & Director Conference Call Participants David A. Amsellem - Piper Sandler & Co., Research Division Jo...
Positive
The Motley Fool
5 days ago
Collegium (COLL) Q2 Revenue Jumps 29%
Neutral
GlobeNewsWire
6 days ago
– Generated Record Quarterly Net Revenue of $188.0 Million, Up 29% Year-over-Year – – Generated Record Quarterly Jornay PM ® Net Revenue of $32.6 Million and Grew Prescriptions by 23% Year-over-Year – – Generated Net Revenue of $155.4 Million from the Pain Portfolio, Up 7% Year-over-Year with All Three Core Products Recording Revenue Growth in the Quarter – – Raised Full-Year 2025 Net Revenue G...
More Collegium Pharmaceutical, Inc. News

Company Profile

Collegium Pharmaceutical, Inc. operates as a pharmaceutical company, which engages in the developing and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. Its products include Xtampza ER, Nucynta ER and Nucynta IR. The Xtampza ER provides pain control while maintaining its extended-release drug release profile after being subjected to common methods of abuse and accidental misuse. The Nucynta ER for the treatment of chronic pain and neuropathic pain associated with diabetic peripheral neuropathy. The Nucynta IR is a release formulation of tapentadol indicated for the management of acute pain severe enough to require an opioid analgesic. The company was founded by Michael Thomas Heffernan in October 2003 and is headquartered in Stoughton, MA.

Head office United States
CEO Vikram Karnani
Employees 357
Founded 2002
Website www.collegiumpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today